Kornimate/medical-research-clean huggingface dataset:
clinical evaluation of the nanodetect-tb mycobacterium tuberculosis detection kit for the diagnosis of tuberculosis disease

Conditions: Tuberculosis, Pulmonary; Tuberculosis, Extrapulmonary; Tuberculosis Active

Summary: the goal of this observational study is investigate the accuracy of the nanodetect-tb kit in diagnosing tuberculosis (tb) using frozen serum and plasma samples collected from individuals suspected to have tb disease. the main question\[s\] it aims to answer are: * how does this investigational device compare to the gold standard for tb diagnosis of sputum culture? * how does it compare to acid-fast bacteria (afb) smear microscopy and fda-approved naat tb diagnostic assays? participants will be asked to have blood drawn and provide demographic and medical data for this study in a single visit.


Eligibility criteria:
inclusion criteria: * children and adults aged two years or older (including older adults that are 65+) * ability and willingness to provide informed consent/assent/permission, and a parent/legal guardian willing to give consent on the child's behalf for study participants aged 2-17 years * ability and willingness to perform study procedures, or parent/legal guardian to provide consent for a child to undergo study procedures on their behalf (when applicable) * clinical signs and symptoms typically associated with active tb disease including, but not limited to: cough for \> two (2) weeks lethargy, weakness, malaise reduced playfulness (pediatric population) weight loss or loss of appetite failure to thrive (pediatric population) fever chest pain night sweats * physician (or healthcare provider) suspicion of tb disease exclusion criteria: * pregnancy (based on participant-provided information) * any physical or mental health condition for which participation in the study, as judged by the investigator, could compromise the well-being of the subject and/or prevent, limit, or confound protocol-specified procedures * critical illness needing immediate medical care * receipt of treatment for active tb or ltbi in the past 24 months
cross-sectional study of fibromyalgia

Conditions: Fibromyalgia

Summary: this study is designed to collect data on precipitating factors, diagnosis, morbidity, therapy, quality of life, and symptom severity, etc. informations in patients with fibromyalgia.

patients fulfilling 1990 acr criterion for fibromyalgia will be recruited in fibromyalgia outpatient service which is belonged to the department of rheumatism. except collecting patients' demographic and social characteristic informations, rheumatologist also carry out a comprehensive evaluation including patient current history, current medication use, and tender point examination for a diagnosis or confirmation of fibromyalgia and treatment recommendations. patients with fibromyalgia will be asked to fill a set of questionnaires to evaluate their quality of life, symptoms severity, quality of sleep and emotion. the study will be conducted in beijing, china.

Eligibility criteria:
inclusion criteria: * age 18 years or older. * fulfills the american college of rheumatology (acr) 1990 classification criteria for fibromyalgia. exclusion criteria: * don't fulfill any classification criterions for fibromyalgia.
proton radiation therapy for invasive breast cancer following mastectomy

Conditions: Invasive Breast Cancer

Summary: in this study we are looking at a type of radiation called proton radiation which is known to spare surrounding tissue and organs from radiation. the proton radiation will be delivered using 3d conformal proton radiation or scanned beam/impt (intensity modulated proton radiation treatment). proton radiation delivers no dose beyond the region requiring treatment. this may reduce side effects that patients would normally experience with conventional radiation therapy or other means of delivering proton radiation therapy. in this study we are evaluating the effectiveness of using proton radiation delivered to reduce side effects association with radiation treatment.

proton radiation will be delivered daily for approximately 5 1/2 weeks. patients will be assessed weekly for any side effects they may be experiencing. patients will have follow-up visits 4 weeks after proton therapy ends, at 6 months, 12 months, and then every year for up to five years after treatment. follow-up visits will include a physical examination, radiological imaging (if necessary), echocardiogram, and laboratory tests.

Eligibility criteria:
inclusion criteria: * histologically confirmed invasive breast cancer confined to the breast and regional lymphatics * completed mastectomy (complete not partial )breast surgery +/- reconstructive surgery * life expectancy \> 12 months exclusion criteria: * pregnant or breast-feeding * prior therapeutic radiation \> 200 cgy * history of a different malignancy unless disease-free for at least 5 years or diagnosed and treated cervical cancer in situ, or basal or squamous cell cancer of the skin * prior investigation chemotherapy

Keywords: breast cancer mastectomy
localized body cooling technology on sleep and metabolism in african, american with overweight and obesity

Conditions: Overweight or Obesity

Summary: the goal of this study is to see the effect that a cooling pillow pad called moona has on sleep quality.

obesity and diabetes pose a signiﬁcant burden on healthcare systems worldwide. evidence from large cross-sectional and longitudinal epidemiologic studies, and well-designed experimental sleep manipulations, demonstrated that insufficient sleep is a risk factor for obesity-induced insulin resistance and type 2 diabetes. limited available evidence suggests that optimizing sleep duration and quality in individuals who experience deficient sleep could have beneficial effects on weight maintenance, facilitate weight loss and improve glucose metabolism. it is well known that body temperature impacts sleep. a rapid decline in core body temperature increases the likelihood of sleep initiation and may facilitate an entry into the deeper stages of sleep. pharmacological treatment is often prescribed for sleep disturbances, primarily insomnia. but sleep extension with benzodiazepines/sedative-hypnotic agents does not appear to have beneficial effects on metabolism, in fact, these drugs may even have an adverse effect on glucose metabolism. many people use melatonin as a sleep aid, however, the available data do not support a major role of melatonin in body weight regulation and the evidence supporting melatonin administration in improving glucose metabolism has been mixed. limited studies suggest that localized cooling could represent a non-pharmacological strategy to favor sleep onset or improve sleep duration and/or quality.

Eligibility criteria:
inclusion criteria: * african american men and women * aged 21-50 years * bmi ≥ 27 to 45 kg/m2 * self-report of short or poor sleepers (\>5 \ 5 on the psqi), * sleeping between 22:00 and 08:00. * ability to provide informed consent before any trial-related activities * controlled hypertension or dyslipidemia. exclusion criteria: * previous diagnosis or reveled during the screening psg (polysomnography) of obstructive sleep apnea (ahi≥30) or other sleep disorders based on dsm-v (diagnostic and statistical manual of mental disorders, fifth edition) criteria. * shift work * diagnosis of diabetes based on history or screening tests * history of cognitive or other neurological disorders * history of major psychiatric disorder based on dsm-v criteria * presence of unstable or serious medical conditions * use within the past month of melatonin, psychoactive, hypnotic, stimulant or pain medications (except occasionally) * caffeine consumption of greater than 500 mg per day * medically managed weight loss program within the past 6 months * history of bariatric weight loss surgery. * women who are pregnant, plan on becoming pregnant, are breastfeeding, * men or women who have a child at home that does not sleep through the night. * active drug/alcohol dependence or abuse
vitamin d effect in rheumatoid arthritis.

Conditions: Active Rheumatoid Arthritis

Summary: regulatory t (tregs) cells play an important role in the maintenance of immunological tolerance. it decrease in the peripheral blood of rheumatoid arthritis patients. vitamin d has an immunomodulatory and anti-inflammatory effect in rheumatoid arthritis. vitamin d supplementation significantly enhances tregs percentage in the peripheral blood of ra patients. so supplementation of vit d improves rheumatoid arthritis disease activity.

background: regulatory t cells (tregs) play an important role in the maintenance of immunological tolerance, so tregs deficiency or decrease suppressor functions may be associated with development of autoimmune diseases. vitamin d is essential for normal bone mineralization and growth, prevention of osteopenia, osteoporosis, and nonspecific painful musculoskeletal conditions . vitamin d is thought to have an immunomodulatory and anti-inflammatory actions, as its receptors are widely expressed in peripheral mononuclear blood cells, also its deficiency associated with several autoimmune disorders, including rheumatoid arthritis methods: 40 patients with active ra were randomly assigned into two groups. group i received mtx plus hydroxychloroquine, group ii received mtx and hydroxychloroquine plus vitamin d supplementation for 3 months, in addition to 30 healthy volunteers as control group. peripheral blood tregs were measured by flow cytometry. statistical analysis. the collected data analyzed by spss software (version 16). the range, mean and standard deviation were calculated for quantitative variables. categorical variables were expressed as number and percentages; chi square was used as a test of their significance. skewness, kurtosis; shapiro-wilk, and the kolmogorov-smirnov tests were used to test the normality for the data. the difference between two means was analyzed using the students (t) test (paired and unpaired samples- t tests). significance was considered at p\<0.05.

Eligibility criteria:
inclusion criteria: * disease duration less than 3 years from the time of diagnosis, age more than 18 years, a diagnosis of ra according to the 2010 acr/ eular classification criteria for ra diagnosis , active disease according to das-28, for those receiving nonsteroidal anti-inflammatory drugs and corticosteroids, the dosage had to be stable for at least 2 weeks before screening. exclusion criteria: * patients with allergic, and infectious diseases, patients receiving steroids for the first time within 2 weeks before the study, patients with hypercalcemia, hypercalciuria, nephrolithiasis, or neoplastic diseases were excluded from the study. we also excluded patients on any biologic therapy and patients with prior use of leflunomide, hydroxychloroquine, or sulphasalazine for more than 2 months.

Keywords: regulatory t cell foxp3+ vitamin d supplementation rheumatoid arthritis dmard
osteoporosis choice decision aid for use of bisphosphonates in postmenopausal women

Conditions: Osteoporosis; Bone Loss, Age Related; Postmenopausal Bone Loss; Postmenopausal Osteoporosis

Summary: to develop a decision aid to support the decision to use (or not use) bisphosphonates in postmenopausal women at risk for osteoporotic fractures, and to assess the impact of the decision aid on start and six month adherence to bisphosphonates.

bisphosphonates can reduce fracture risk in patients with osteoporosis. however, many patients may not start and adhere to bisphosphonates, consequently losing independence, quality, and length of life. we hypothesize that a decision aid that efficiently improves patient education and communication with their provider about fracture risk, and about using bisphosphonates to reduce that risk, will improve the quality of treatment decisions. we anticipate that patients will become more involved in the decision-making process and decisions will be more consistent with patients' values and health care goals. we expect this will lead to increased bisphosphonate start and adherence and improved patient outcomes.

Eligibility criteria:
inclusion criteria: * female, post-menopausal women aged 50 to 90. * have a bone mineral density (bmd) evaluation resulting in a t-score of \<-1.0. * have a follow-up appointment with a provider in the areas of family medicine (fm), primary care internal medicine (pcim), or pom. * have no major barriers (i.e., severe hearing impairment, dementia, require interpreter, etc.) to participation in shared decision-making (per provider's assessment) * enrollment is open to females of diverse racial backgrounds. exclusion criteria: * currently taking a bisphosphonate. * not available for 6 month follow-up phone call.

Keywords: osteoporosis, age-related osteoporosis, postmenopausal bone loss low bone density
occurrence of pneumocystis pneumonia in hiv-infected patients and the interference of the haart

Conditions: HIV

Summary: from the beginning of the aids epidemic, pulmonary pneumocystosis (pcp) has been distinguished as one of the most frequent opportunistic diseases with high morbid-mortality. as from 1996, the advent of the highly active antiretroviral therapy (haart) has changed the characteristics of such epidemic by reducing its related diseases and, as a result, aids-related mortality. with the purpose to estimate pcp occurrence and haart interference, 376 hiv-infected or aids patients were studied from january 1992 to december 2002.

from the beginning of the aids epidemic, pneumocystis pneumonia (pcp) has been distinguished as one of the most frequent opportunistic diseases with high morbid-mortality. as from 1996, the advent of the highly active antiretroviral therapy (haart) has changed the characteristics of such epidemic by reducing its related diseases and, as a result, aids-related mortality. with the purpose to estimate pcp occurrence and haart interference, 376 hiv-infected or aids patients were studied from january 1992 to december 2002. among them, 58 (15.5%) pcp cases were found. there was a higher occurrence of pcp in the group of patients in which haart was not used, with 40 (69.0%) of the episodes. as regards the studied period, a tendency to a linear reduction in annual pcp incidence was observed. the mean of t cd4+ lymphocytes in the patients with pcp (117 cells/mm3) was significantly lower when compared to that of the other individuals (325 cells/mm3). therefore, this study suggests a temporal reduction in pcp occurrence related to haart use with higher t cd4+ lymphocyte counts. nevertheless, this opportunistic infection still shows significant incidence in aids patients.

Eligibility criteria:
inclusion criteria: * hiv infection exclusion criteria: * no hiv infection

Keywords: pneumocystis pneumonia acquired immune deficiency syndrome highly active antiretroviral therapy treatment experienced treatment naive
influence of preoperative fluid intake on the onset of postoperative acute kidney injury

Conditions: Thoracic Surgery; Acute Kidney Injury; Critical Care

Summary: to investigate the influence of preoperative fluid and food intake in cardiac surgery patients on the development of postoperative aki.

acute renal failure (arf) and the need for renal replacement therapy (rrt) is a major complication after cardiac surgery, associated with mortality and an increased risk to develop end-stage renal disease. cardiac surgery patients are at increased risk to develop acute kidney failure due to ischaemia-reperfusion injury, cardiopulmonary bypass (cpb) induced inflammation and haemolysis, hemodynamic alterations, vasoconstriction and resulting reduced renal perfusion. according to the current literature, aki occurs in average in 20-30% after cardiac surgery with an incidence of rrt in 1-5%. several reviews revealed the literature and concluded that , inter alia, euvolemia, adequate nutrition, the avoidance of nephrotoxic drugs and anemia optimization belong to the most effective prevention strategies. patients are instructed to follow the nil per os (npo) guidelines, including abstinence of clear liquids for \>2 hours preoperative as well as fasting time of light foods for \> 6 hours and fatty foods for \>8 hours prior to surgery. however, these guidelines encourage patients to continue po hydration until 2 h before surgery in order to optimize the volume status. besides the fact that npo lasts in average critically longer than required, surgery delay is a common issue and may lead to an exceedance of npo up to twice as long as required. data about the exact mechanism is still sparse, but preoperative iv hydration may correct or even expand intravascular volume, improve renal perfusion and induce diuresis, stimulate endogenous natriuretic peptides release and inactivate the renin-angiotensin-aldosterone system (raas). large trials on this very relevant topic in these high risk cardiac surgery patients are absolutely missing. therefore, this prospective observational study aims to investigate the influence of varied preoperative fluid and food intake in cardiac surgery patients on the development of postoperative aki.

Eligibility criteria:
inclusion criteria: * adult patients (\>18 years of age) scheduled to undergo elective cardiac surgery with the use of cardiopulmonary bypass (cpb) and cardioplegic arrest exclusion criteria: * patients not willing to participate or not able to give informed consent * patients receiving contrast agents within 72 hours before surgery * patients with preoperative need for renal replacement therapy * patients receiving an extracorporeal mechanical assist device (e.g. ecls) or for advanced heart failure therapies (e.g. tah, vad) will be excluded. * patients participating in another interventional trial * pregnant or lactating patients

Keywords: cardiac surgery patients acute renal failure intensive care
examining the feasibility and acceptability of good quality intensive cbt for ocd and good quality weekly cbt for ocd

Conditions: Obsessive Compulsive Disorder (OCD)

Summary: the purpose of this study is to examine how feasible and acceptable it is to deliver a talking treatment called cognitive behavioural therapy (cbt) in two different formats for people who have had treatment for ocd in the past but it didn't work out for them. the two different treatment formats are cbt delivered on a weekly basis (which is approximately 12-18 hours of therapy delivered weekly for 60-90 minutes each session, followed by 1-3 monthly follow up sessions as needed) and cbt offered in an intensive format (which is having approximately 12-18 hours of therapy all in a 3-week period, followed by 1-3 monthly follow up sessions as needed).

the main aim of this study is to assess the feasibility and acceptability of intensive cbt for treatment resistant ocd when participants are randomized to this format. this study aims to establish an estimate of the relative efficacy of both intensive and weekly cbt when compared individually to wait list, for participants with a diagnosis of ocd, who have previously not responded to cbt.

Eligibility criteria:
inclusion criteria: * primary diagnosis of ocd (as confirmed by the administration of the structured clinical interview for diagnostic and statistical manual of mental disorders, 4th ed.) (dsm-iv) (scid-i) . * participant identifies their main problem as ocd. * participant has not responded to one or more trials cbt * yale-brown obsessive compulsive scale (ybocs) score of 16 or above. * no change in psychotropic medication (if applicable) for at least 8 weeks prior to study entry. (if such a change has taken place there will be an option for the participant to take part once the medication has been stabilised). * no intention to change psychotropic medication during the course of the trial * able to speak and read every day english exclusion criteria: * severe psychiatric problem that requires separate treatment at an immediate basis and is linked to risk. * drug and/or alcohol dependence in last three months * history of psychosis or bipolar disorder

Keywords: obsessive compulsive disorder (ocd) cognitive behavioural therapy (cbt) intensive therapy intensive treatment treatment resistant
study of cp-751,871 in combination with docetaxel and prednisone in patients with hormone insensitive prostate cancer (hrpc)

Conditions: Prostatic Neoplasms

Summary: to test the efficacy of cp-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy


Eligibility criteria:
inclusion criteria: * diagnosis of metastatic, progressive hormone refractory prostate cancer * adequate bone marrow, liver and kidney function exclusion criteria: * previous treatment with chemotherapy

Keywords: randomized non-comparative efficacy
plating of humeral shaft fractures in multiple trauma patients.

Conditions: Humeral Fractures; Multiple Trauma

Summary: the purpose of this study is to review our experience with the operative management of acute diaphyseal fractures of the humerus via an anterolateral approach with the use of small fragment fixation at a level i, urban, trauma center. we will report our clinical and radiographic results, complication rate and final range of motion. a standardized outcome measurement (dash) will be reported. muscle recovery of the triceps and biceps will be evaluated by a standard protocol, accomplished with the assistance of a licensed physical therapist. we hypothesize that open reduction and internal fixation of humeral diaphyseal fractures via an antero-lateral approach with the use of small fragment fixation is a safe and efficacious way to treat multiple trauma patients with these injuries.


Eligibility criteria:
inclusion criteria: * age \> 18 years * patients with past (acute) traumatic humeral shaft fracture(s) treated with open reduction and internal fixation (orif) * patients for whom the above fracture has healed * patients willing and able to provide informed consent and able to participate in study procedures exclusion criteria: * patients with known pathological fractures * patients with metabolic bone disease * patients with humeral head or inter-articular surface fractures, or other upper extremity fractures * patients with previous humeral surgery (i.e. rotator cuff, biceps tendon, etc.) * patients with neurologic injury to upper extremities